glut1

GLUT1-IN-1, a glucose transporter 1 (GLUT1) inhibitor, possesses specific inactivation capability for GLUT1. This compound demonstrates concentration-dependent cytotoxicity towards HeLa, A549, and HepG2 cells, with IC50 values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. It is utilized in the research of photodynamic therapy (PDT) and several cancers [1].

GLUT1-IN-3 (Compd 4b), a compound under investigation for type 1 glucose transporter deficiency syndrome, effectively inhibits seizures [1].

GLUT inhibitor-1 is an orally active GLUT inhibitor with IC50 s of 242 nM and 179 nM for GLUT1 and GLUT3. GLUT inhibitor-1 can be used in studies about cancers and autoimmune diseases.

Triheptanoin (IND 106011) is a fatty acid metabolic modulator. It potentially for the treatment of fatty acid oxidation disorders and GLUT1.

BAY-876 is an orally active, selective inhibitor of glucose transporter 1 (GLUT1, IC50= 2 nM), exhibiting over 130-fold greater selectivity for GLUT1 than GLUT2, GLUT3, and GLUT4. It also inhibits glycolytic metabolism and ovarian cancer growth.

WZB117 is a Glucose Transporter 1 (GLUT1) inhibitor. when IC50 of WZB117 approximate 10 μM, it inhibits lung cancer A549 cells and breast cancer MCF7 cells proliferation.

AS1949490 activated glucose metabolism via up-regulation of GLUT1 gene in L6 myotubes[1][2]. AS1949490 is a potent and selective SHIP-2 (SH2 domain-containing inositol 5′ phosphatase 2) inhibitor, with an IC50 of 620 nM.

Fasentin (N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide) is an inhibitor of GluT1.

hydrocotarnine is an inhibitor of Cbl.

Lavendustin B is a Tyrosine Kinase Inhibitor and an inhibitor of HIV-1 integrase (IN) interaction with its cognate cellular cofactor, lens epithelium-derived growth factor (LEDGF/p75).

KL-11743 specifically blocks glucose metabolism, triggering an acute collapse in NADH pools and a striking accumulation of aspartate, indicating a dramatic shift toward oxidative phosphorylation in the mitochondria.

Marein shows neuroprotective effect on PC12 cell damage induced by methylglyoxal, which is due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway, it may be a potent compound for preventing/counteracting diabetic e

NV-5440 is a novel cell penetrant, potent and selective class I glucose transporters (GLUT1) inhibitor, selectively inhibiting mTORC1

KRH102140 is a potent activator of PHD2. KRH102140, which has a structure similar to KRH102053. KRH102140 more efficiently suppressed HIF-1α than KRH102053 in human osteosarcoma cells under hypoxia. Furthermore, KRH102140 decreased the mRNA levels of HIF-regulated downstream target genes associated with angiogenesis and energy metabolism such as vascular endothelial growth factor, adrenomedullin, Glut1, aldolase A, enolase 1 and monocarboxylate transporter 4. KRH102140 also inhibited tube formation in human umbilical vein endothelium cells. The results suggest that KRH102140 has potential therapeutic effects in alleviating various diseases associated with HIFs.

STF-31 is an inhibitor of glucose transporter 1 (GLUT1) with IC50 of 1 μM.

GLUT4-IN-2 is a specific GLUT4 inhibitor that inhibits GLUT1 and GLUT4.GLUT4-IN-2 has antitumor activity, induces apoptosis and cell cycle arrest, and can be used for cancer research.

4,6-O-Ethylidene-α-D-glucose (Ethylidene-glucose), a derivative of glucose, serves as a competitive inhibitor for the exofacial binding site of glucose transporter 1 (GLUT1), exhibiting a Ki of 12 mM against wild-type 2-deoxy-D-glucose transport.

AS1938909 is a SHIP2 inhibitor that works by increasing Akt phosphorylation, glucose consumption, and glucose uptake in L6 myotubes, specifically upregulating the GLUT1 gene.

BAY-588 is an inactive control probe of BAY-876 which is an inhibitor of GLUT1.